- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sanofi offers to buy biotechnology firm Kiadis for USD 358.4 million
New Delhi: Sanofi is offering to buy Dutch biotechnology company Kiadis for 308 million euros ($358.4 million) to boost its range of immunotherapy products.
The French drugmaker will offer 5.45 euros in cash, the companies said in a joint statement on Monday, a premium of 272% to Kiadis' closing share price on Oct. 30.
Shares in Kiadis, focused on cell-based immunotherapy products for the treatment of cancer, were up 245% in early trading. Sanofi shares were up 1.18%.
Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells.
"We believe Kiadis 'off the shelf' K-NK cell technology platform will have broad application against liquid and solid tumors, and create synergies with Sanofi's immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches," said John Reed, global head of research and development at Sanofi.
The deal is the latest in a series of bolt-on transactions for Sanofi. In August, it spent $3.7 billion to buy U.S. autoimmune diseases specialist Principia Biopharma following a $2.5 billion investment to acquire immuno-oncology treatments group Synthorx in December last year.
Sanofi was late to capitalise on the takeoff of immunotherapy - drugs that activate the body's immune system to attack tumor cells - in the early 2010s.
It is now trying to catch up and is focusing on a pipeline of several medicines that it hopes will secure it a piece of the $100 billion-a-year cancer drug market.
Sanofi said Kiadis' medicines will be developed alone and in combination with Sanofi's existing platforms.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751